Fairmount Discloses 19.99% Alaunos Stake After Velaris Merger and $350M PIPE

summarizeSummary

Fairmount reported a 19.99% stake in Alaunos (858,789 shares, $100.2M aggregate cost) following the October 13 Velaris merger and $350M PIPE, with board control, operating covenants and a 180-day lock-up attached. Because the preferred converts at 1,000-for-1, a stockholder vote to authorize the shares and approve conversion is the next gate.

check_boxKey Events · Ownership and Investor Activity · TCRT

• Fairmount Reports 19.99% Alaunos Stake

  Fairmount funds hold 858,789 shares (687,789 common plus 171,000 as-convertible Series C), equal to 19.99% of Alaunos, at an aggregate purchase price of $100,199,073.47.

• Preferred Converts 1,000-for-1 Pending Vote

  105,286 Series B and 33,054 Series C shares each convert into 1,000 common shares, roughly 138.3 million shares against 3,440,670 common shares outstanding as of September 30, 2026, but only after stockholders approve the Conversion Proposal and Authorized Share Increase.

• Lead Investor Gains Board Control

  Three directors resign and Lead Investor designees are appointed so Velaris and Lead Investor designees hold four of five board seats; Series B holders elect two directors whose votes count three times on board matters.

• Operating Plan Locked to Lead Investor

  Until conversion, 12 months post-closing or earlier agreement, Alaunos must run Velaris programs per the agreed development plan and budget and cannot materially deviate without Lead Investor consent.

auto_awesomeAnalysis · TCRT · Life Sciences

This 13D provides the first hard ownership accounting for the Velaris deal: Fairmount's funds hold 858,789 shares, or 19.99% of Alaunos, at an aggregate cost of $100,199,073.47 across common, Series B and Series C preferred. Because a 19.99% blocker caps the stake and automatically drops to 9.99% once the group falls to 9.0% or less, the reported percentage is a ceiling, not a floor. More consequential than the number is the control package attached to it: three directors resign and Lead Investor designees are appointed so Velaris and Lead Investor designees hold four of five board seats, Series B holders elect two directors whose votes count triple on board matters, and the company cannot materially deviate from the agreed Velaris development plan or budget without Lead Investor consent. A 180-day lock-up covers shares held at closing, and a resale registration statement is due within 30 days of the October 14 close. For existing holders, the dilution math is the real story: 105,286 Series B and 33,054 Series C shares convert at 1,000 common shares each, roughly 138.3 million shares against 3,440,670 common shares outstanding as of September 30, 2026, which is why the company must first win a stockholder vote to increase authorized shares and convert. That vote, plus the reverse split and name change bundled into the same proxy, is the next event that matters.